Herpes Simplex Encephalitis

Open Access
Publisher Website
Google Scholar
Abstract
To the Editor: In a recent decision analysis of clinical management of suspected herpes simplex encephalitis, using published quantitative data and subjective estimates of important probabilities provided by experts in management of this condition, I reported that administering vidarabine to patients with a high likelihood of herpes simplex encephalitis, rather than basing the decision on whether or not to use vidarabine on brain biopsy, is consistent with higher expected survival.1 This result depends to a small extent on the possibility of serious complications due to the biopsy and on the apparent low toxicity of vidarabine. The major liability of the . . .

This publication has 4 references indexed in Scilit: